Shares of Bio-Techne (TECH) were up Tuesday morning after the life sciences company said it prevailed in a second claim of reverse engineering of its antibodies by Mitlenyi Biotec.
The company said a court in Germany ruled that Miltenyi Biotec commercialized antibodies developed based on information obtained by reverse engineering certain branded antibodies of Bio-Techne.
The court found that Miltenyi has been marketing and selling those antibodies and determined that Bio-Techne is entitled to monetary damages related to sales of such antibodies, among other costs, Bio-Techne said.
Miltenyi didn't immediately respond to MT Newswires' request for comment.
Price: 75.65, Change: +1.40, Percent Change: +1.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.